SCHEMBL29081302

SCHEMBL29081302

CC1CC[C@@H](c2ccc(Br)cc2)NC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.38
CYP2C9 P11712 4/20 0.38
CYP2C19 P33261 3/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
ALOX15 P16050 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ALDH1A1 P00352 1/20 0.36
KDM1A O60341 5/20 0.34
KCNH2 Q12809 2/20 0.34
MAOB P27338 2/20 0.34
RCOR1 Q9UKL0 2/20 0.34
KDM1B Q8NB78 1/20 0.34
CYP2D6 P10635 1/20 0.33
ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25907988 1.00 CYP3A4 (0.38) CYP3A4CYP2C9CYP2C19LMNATSHR
SCHEMBL29081300 1.00 CYP3A4 (0.38) CYP3A4CYP2C9CYP2C19LMNATSHR
SCHEMBL14963942 0.83 MAPT (0.39) CYP3A4CYP2C9CYP2C19LMNAMAPT
SCHEMBL24233794 0.83 MAPT (0.39) CYP3A4CYP2C9CYP2C19LMNAMAPT
SCHEMBL25321512 0.83 MAPT (0.39) CYP3A4CYP2C9CYP2C19LMNAMAPT
SCHEMBL25334787 0.82 CYP2A6 (0.34)
SCHEMBL24363974 0.81 KCNH2 (0.37) TSHRTDP1KDM1AKCNH2ESR2
SCHEMBL24233839 0.81 DRD2 (0.36) ALDH1A1ESR2
SCHEMBL24363851 0.81 KCNH2 (0.37) TSHRTDP1KDM1AKCNH2ESR2
SCHEMBL31145247 0.81 ESR2 (0.53) CYP3A4CYP2C9CYP2C19MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116568677-A piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers 探戈医药股份有限公司 2023-08-08 CN disclosed